Clonal relatedness between lobular carcinoma  and synchronous malignant lesions by unknown
RESEARCH ARTICLE Open Access
Clonal relatedness between lobular carcinoma
in situ and synchronous malignant lesions
Victor P Andrade1, Irina Ostrovnaya2, Venkatraman E Seshan2, Mary Morrogh3, Dilip Giri4, Narciso Olvera5,
Marina De Brot6, Monica Morrow3, Colin B Begg2 and Tari A King3*
Abstract
Introduction: Lobular carcinoma in situ (LCIS) has been accepted as a marker of risk for the development of
invasive breast cancer, yet modern models of breast carcinogenesis include LCIS as a precursor of low-grade
carcinomas. We provide evidence favoring a clonal origin for LCIS and synchronous estrogen receptor-positive
malignant lesions of the ductal and lobular phenotype.
Methods: Patients with prior LCIS undergoing mastectomy were identified preoperatively from 2003 to 2008.
Specimens were widely sampled, and frozen blocks were screened for LCIS and co-existing malignant lesions, and
were subject to microdissection. Samples from 65 patients were hybridized to the Affymetrix SNP 6.0 array
platform. Cases with both an LCIS sample and an associated ductal carcinoma in situ (DCIS) or invasive tumor
sample were evaluated for patterns of somatic copy number changes to assess evidence of clonal relatedness.
Results: LCIS was identified in 44 of the cases, and among these a DCIS and/or invasive lesion was also identified
in 21 cases. A total of 17 tumor pairs had adequate DNA/array data for analysis, including nine pairs of LCIS/
invasive lobular cancer, four pairs of LCIS/DCIS, and four pairs of LCIS/invasive ductal cancer. Overall, seven pairs
(41%) were judged to be clonally related; in five (29%) evidence suggested clonality but was equivocal, and five
(29%) were considered independent. Clonal pairs were observed with all matched lesion types and low and high
histological grades. We also show anecdotal evidence of clonality between a patient-matched triplet of LCIS, DCIS,
and invasive ductal cancer.
Conclusion: Our results support the role of LCIS as a precursor in the development of both high-grade and low-
grade ductal and lobular cancers.
Introduction
Since the original description of lobular carcinoma in situ
(LCIS) by Foote and Stewart in 1941 [1], confusion has
existed about its management. Historical data suggest
that LCIS is not an obligate precursor to invasive disease,
and LCIS has until relatively recently been accepted as a
risk factor for the development of invasive breast carci-
noma (lifetime risk, 20 to 25%) in both the affected breast
and the nonaffected breast [2-5]. Emerging laboratory
findings supporting a precursor role for LCIS in the
development of invasive lobular carcinoma (ILC) include
the presence of shared molecular alterations in LCIS and
co-existing ILC in a small number of archival specimens
[6-8]. Specifically, comparative genomic hybridization
studies have demonstrated losses on chromosomes 16q
and 17p in both LCIS and ILC [9-11], truncating muta-
tions in the E-cadherin gene and loss of heterozygosity
(LOH) of the wild-type E-cadherin allele have been found
in LCIS and adjacent ILCs [12], and studies have sug-
gested a clonal relationship in a small number of co-
existing LCIS and ILC tumors [6-8]. More recently,
shared patterns of LOH were identified in a small study
of LCIS and adjacent ductal lesions contributing to an
emerging molecular concept that LCIS may be one of
several early identifiable lesions in the pathogenesis of
low-grade carcinomas [13].
Although provocative, current molecular data are lim-
ited in number and nature, largely due to the use of
archival paraffin-embedded tissues. The objective of this
study was to elucidate the clonal relationship between
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LCIS and related malignant lesions of the breast using
purified cell populations from fresh frozen tissue speci-
mens in a study of systematically collected specimens
from patients undergoing mastectomy.
Materials and methods
Patients with a documented history of LCIS undergoing
risk-reducing mastectomy or therapeutic mastectomy
for a new diagnosis of breast cancer at Memorial Sloan-
Kettering Cancer Center, New York, USA were identi-
fied preoperatively, informed consent was obtained, and
patients were prospectively enrolled on a Memorial
Sloan-Kettering Cancer Center Institutional Review
Board-approved protocol from 2003 to 2008. The ethics
committee that approved the protocol was the Memorial
Sloan-Kettering Cancer Center Institutional Review
Board. Microarray data were generated in the Genomics
Core Lab at Memorial Sloan-Kettering Cancer Center.
Following routine clinical sampling, up to 10 frozen
blocks from each quadrant of the breast(s) were collected
from the mastectomy specimens for the purposes of this
study. H & E-stained sections 5 μm thick from the frozen
blocks were systematically screened for LCIS, invasive car-
cinoma, and the presence of other high-risk lesions,
including ductal carcinoma in situ (DCIS). Selected frozen
blocks were used to prepare 10 to 15 μm thick sections for
laser capture microdissection (P.A.L.M. HAL 100; Carl
Zeiss Microimaging, Inc., Thornwood, NY, USA) as pre-
viously described by our group [14]. DNA was extracted
(Qiagen DNAtissue Kit; Qiagen Benelux B.V., Venlo, the
Netherlands) from 140 laser-capture microdissected sam-
ples representing 65 patients who consented to the pro-
spective study, and samples were submitted to the
Affymetrix SNP 6.0 microarray platform. For this analysis,
we restricted attention to patients who had both an LCIS
sample and an associated DCIS or invasive tumor sample.
Clinical formalin-fixed paraffin-embedded (FFPE) slides
were also obtained for all cases. The histologic subtype
was defined as described by the College of American
Pathologists Consensus Statement [15]. Briefly, classic lob-
ular carcinomas demonstrated low neoplastic cell density,
monotonous grade 1 nuclei, low mitotic activity, and cellu-
lar dishesion, with or without targetoid infiltration, in at
least 90% of the neoplastic cell population. The diagnosis
of infiltrating mammary carcinoma with mixed ductal and
lobular features was made in cases that had a component
showing ductal differentiation (in the form of tubule for-
mation) and areas with a lobular growth pattern (Indian
file arrangement of tumor cells). These tumors typically
had low nuclear grade. Invasive tumors were graded using
the Scarf-Bloom and Richardson system modified by
Elston and Ellis [16], and DCIS was graded according to
the Van Nuys classification [17]. LCIS was classified as
pleomorphic LCIS only when moderate or marked nuclear
atypia was present, with or without necrosis or apocrine
features [18].
Immunohistochemistry (IHC) slides were reviewed to
assess the estrogen receptor (ER), progesterone receptor
(PR), and HER2 status of invasive cancers (and in situ
lesions when present in the same slide). E-cadherin slides
were also reviewed when available. Fresh FFPE sections
were prepared for ER, PR, and HER2 for those cases in
which the in situ lesions (LCIS or DCIS) were not present
on the original IHC slides. Additional E-cadherin staining
was not performed. Care was taken to ensure that the
lesions assessed by IHC were taken from the same quad-
rant of the breast as the lesions that were subject to the
Affymetrix SNP 6.0 microarray platform. Any nuclear
staining was considered positive for ER and PR. HER2
was graded according to the American Society of Clinical
Oncology/College of American Pathologists guidelines
[19]. The characteristics of the antibodies and protocols
used in IHC are shown in Additional File 1.
The SNP arrays were processed using the aroma.affy-
metrix package in R to estimate raw copy numbers [20].
Briefly, the steps included normalizing the arrays to
account for allelic crosstalk, base position, and fragment-
length effects. Multiple probesets per SNP were then
summarized for SNP-level intensity. The average inten-
sity of all the arrays from normal tissues was used as the
reference to estimate the relative copy numbers of indivi-
dual arrays. The total number of probes on the array was
~1.8 million; approximately 316,000 probes that target
known germline copy number variants were excluded. By
averaging blocks of 100 adjacent log-ratios, we reduced
the resolution of the arrays to ~15,000 markers in order
to limit the noise levels. The closeness of identified
paired copy number changes was examined to gauge the
evidence for and against a clonal origin of the tumor
pairs. Briefly, the method involves first segmenting the
arrays to identify the locations of at most one copy num-
ber gain or loss on a chromosome arm [21]. Segments <
2.3 MB in length that overlapped known copy number
variations from the database of genomic variants [22]
were excluded. Correlation in the patterns of gains and
losses between the tumors is then evaluated using the
chromosome arm as the unit of analysis, which is classi-
fied based on the central or most outstanding segment if
there are two or one breakpoints, respectively. Individual
concordant gains or losses are then examined more care-
fully to assess the evidence that each concordant change
could have originated from a clonal (that is, identical)
somatic event. The results are aggregated, and a measure
characterizing the strength of evidence favoring clonality
is calculated. This measure is then benchmarked against
the distribution of the measure in pairs of tumors from
different patients to obtain a P value. Tumor pairs are
considered clonal if the observed similarity measure lies
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outside the reference distribution of independent pairs,
and is considered suggestive for clonality (equivocal) if
the P value is within the range of the reference distribu-
tion but more extreme than the 5th percentile (that is,
P < 0.05). Further details of the method are described in
Ostrovnaya and colleagues [21], and software is available
in the Bioconductor package [23].
The source data used in this study are available in
Dryad Repository [doi:10.5061/dryad.6354b].
Results
LCIS was identified in 44/65 (68%) patients subject to
the array; among these, 21 patients had a paired DCIS
and/or a paired invasive lesion for comparison. Seven
patients were excluded due to poor-quality DNA/array
data, leaving 14 patients with 17 paired samples for ana-
lysis (three patients each had three samples for compari-
son). The characteristics of each of the LCIS and paired
samples are described in Table 1.
As a group, lesions varied in terms of the complexity
of copy number changes. Among lesions of lobular ori-
gin, the most frequent changes observed were 1q gain
and 16q loss. The genome-wide averages of all gains
and losses in LCIS, DCIS, and invasive cancers, includ-
ing partial-arm changes, are displayed in Figure 1. Over-
all, although the frequencies of allelic changes are
slightly less in the in situ lesions, the general pattern of
broad genetic instability is similar. The most frequently
observed whole-arm gains and losses for LCIS, DCIS,
and invasive lesions are ranked in Additional File 2.
Of the 17 pairs evaluated, seven (41%) were classified
as clonal, five (29%) as equivocal, and five (29%) as inde-
pendent (Table 1). Clonal pairs were observed with all
matched lesion types; that is, both ductal and lobular,
and low and high histological grades. Selected examples
of individual segmented arrays from three cases (Case
#122, Case #84, and Case #93) are provided in Figure 2.
Similar plots for all cases are provided in Additional File
3. Case #122 is an example of LCIS and paired ILC
(both of pleomorphic morphology) with convincing evi-
dence of clonality. The broad patterns of segmented
changes are very similar, and there are several within-
chromosome changes that are very closely matched; for
example, on 2p, 8p, 11q, and 16q.
Case #84 is an example of paired LCIS and cribriform
low-grade DCIS where the immediate visible evidence is
much less clear cut in that allelic changes are not easily
visible due to the noise in the arrays. However, this is
an example where the statistical algorithm is especially
useful. The within-chromosome-arm segmentation
method detects closely matching changes on several
chromosome arms; that is, 5q, 7p, 9q, 10q, 11q, and
16p. These matches can be observed more clearly by
examining individual chromosome arms. Figure 3
displays these changes, clearly showing the closeness of
the matching gains and losses. Chromosome-specific
plots are provided for all cases in Additional File 4.
It is harder to find convincing evidence that tumor
pairs are independent, since we have to be confident
that we have not failed to detect true clonal changes.
Case #93 involving LCIS and an ILC solid variant has
the ubiquitous matching whole-arm gains on 1q and
losses on 16q, and a few other matching whole-arm
changes (Figure 2), but there are many nonmatching
changes and no concordant gains or losses within an
individual chromosome arm. Consequently, in this case
there is no strong evidence that the tumors are clonal.
For all five cases classified as independent (Case #32,
Case #43, Case #121, Case #120, and Case #83), an
examination of the detailed arm-by-arm changes in
Additional File 4 shows that where evidence of allelic
changes is detected they are rarely overlapping for the
tumors being compared. Representative photomicro-
graphs of Case #122 (paired pleomorphic LCIS and ILC
determined to be of clonal origin) and Case #93 (paired
classic LCIS and ILC determined to be of equivocal ori-
gin) are provided in Additional File 5.
The measures representing the strength of evidence
for clonality from the individual comparisons are plotted
in the red histogram in Figure 4. The black histogram
represents a reference distribution of measures obtained
from analyzing pairs of tumors from different patients.
The seven definitively clonal cases comprise the entries
in the red histogram that lie clearly to the right of the
entire black histogram, and these are identified by their
case numbers below the plot.
As expected, all LCIS, classic ILCs, and low-grade
invasive ductal carcinoma (IDC) were ER-positive and
HER2-negative. All but one of the high-grade lesions (in
situ or invasive) included in this study were also ER-
positive and HER2-negative. The only exception was a
solid high-grade DCIS with a triple-negative profile
(Case #120). Interestingly, the triple-negative case was
considered to be of independent origin from the adja-
cent ER-positive LCIS; while two ER-positive DCIS
cases and two ER-positive IDCs, both low-grade and
high-grade histologies, were considered to be of clonal
origin with the adjacent LCIS. In addition, Case #95
involved three tumor samples (LCIS, DCIS, and IDC),
all of which displayed the same IHC profile and all of
which were determined to be clonal. The photomicro-
graphs of the individual lesions for Case #95 and the
respective genome-wide plots are displayed in Figures 5
and 6, respectively. In these tumors, the broad similarity
of profiles is evident from the plots, although the
matching changes are mostly whole-arm changes.
Although we did not perform E-cadherin immuno-
chemistry systematically in these cases, for the purposes
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of this study clinical slides were available for 9/17 (53%)
pairs (Table 1). In all available cases, E-cadherin staining
was characteristically absent in lobular lesions and pre-
sent in ductal lesions - including Case #84, in which the
LCIS and adjacent DCIS were considered to be of clonal
origin as described above in Figure 2. Representative
photomicrographs of Case #84 are shown in Figure 7.
Case #76, a comparison of LCIS and the invasive lobular
component of the mixed invasive lesion (IDC-LF), also
considered to be of clonal origin, similarly demonstrated
absent E-cadherin staining in both LCIS and the lobular
component of the invasive lesion, while E-cadherin
staining was present in the ductal component (Figure 8).
Finally, data are publically available from an important
previous study by Hwang and colleagues that examined
24 pairs of synchronous LCIS and ipsilateral ILCs
microdissected from FFPE tissue using a bacterial artifi-
cial chromosome array with roughly 1,900 clones cover-
ing the whole genome [7]. We re-analyzed these
24 tumor pairs using the same statistical methodology
as in our analyses. We classified six of the 24 tumor
pairs (25%) as clonal, seven (29%) as equivocal, and 11
(46%) as independent - results broadly consistent with
the interpretations of Hwang and colleagues.
Discussion
Once a woman is diagnosed with LCIS, she faces an
eightfold to 10-fold increased risk for the subsequent
development of breast cancer, the pathogenesis of which
is poorly understood [24,25]. Emerging reports of shared




Histology Gradec IHC profile E-cadherin





#32 Bilateral + + - NA ILC classic I + + - NA 0.07 I
#43 Left + + - NA ILC classic I + + - NA 0.99 I
#93 Left + + - - ILC solid variant II + + - - 0.004 E
#107 Bilateral + + - - ILC classic I + + - - 0.013 E
#114a Bilateral + + - NA ILC classic I + + - NA <
0.001
C
#114b Bilateral + + - NA ILC classic I + + - NA <
0.001
C
#121 Left + + - NA ILC variant II + + - NA 0.30 I
#122 Bilateral + + - - ILC pleomorphic III + + - - <
0.001
C
#126 Right + + - NA ILC classic I + + - NA 0.009 E
LCIS and
DCIS
#84 Bilateral + + - - DCIS cribiform Group
1
+ + - + <
0.001
C
#95 Left + + - NA DCIS micropapillary Group
3
+ + - NA <
0.001
C
#110 Bilateral + + - - DCIS cribiform Group
1
+ + - + 0.031 E
#120 Bilateral + + - - DCIS papillary Group
3
- - - + 0.96 I
LCIS and
IDC-LF





#83 Left + + - - ILC and IDC NST I + + - - 0.12 I
LCIS and
IDC
#95 Left + + - NA IDC NST III + + - NA <
0.001
C
#110 Bilateral + + - - IDC NST and
micropapillary
II + + - + 0.004 E
aSeventeen distinct comparisons of tumor pairs from 14 distinct patients. Case #114 involves samples from two distinct LCIS tumors (one in the upper outer
quadrant and one in the lower outer quadrant) and one invasive lobular tumor. Case #76 involves samples from LCIS and the invasive lobular component of the
mixed lesion. bAny nuclear staining was considered positive for estrogen receptor (ER) and progesterone receptor (PR). HER2 was graded according to the
American Society of Clinical Oncology/College of American Pathologists guidelines [19]. All LCIS lesions were classic LCIS, except Case #122 that was classified as
pleomorphic LCIS [18]. cInvasive cancers were graded according to the Scarff-Bloom and Richardson system modified by Elston and Ellis [16], and DCIS was
graded according to the Van Nuys classification [17]. dC, clonal (P < 0.001); E, equivocal (0.001 <P < 0.05); I, independent (P > 0.05). DCIS, ductal carcinoma in situ;
IDC, invasive ductal carcinoma; IDC-LF, invasive mammary carcinoma with mixed ductal and lobular features; IHC, immunohistochemistry; ILC, invasive lobular
carcinoma; LCIS, lobular carcinoma in situ; NA, not available; NST, no special type.
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molecular alterations between LCIS and adjacent inva-
sive lesions in parallel with genomic evidence that LCIS
may be one of several early identifiable lesions in the
pathogenesis of low-grade cancer have re-opened the
debate regarding the true significance of LCIS and its
precursor potential. Using fresh frozen breast samples
subject to laser-capture microdissection for isolation of
pure cell populations, and using specialized statistical
methods, we report evidence that LCIS is clonally
related to a substantial proportion of the adjacent malig-
nancies studied in this series, including cases of low-
grade and high-grade DCIS and invasive mammary car-
cinoma with mixed ductal and lobular features. In addi-
tion, the immunohistochemical profiles of all cases
considered clonal or equivocal were consistent with the
recent theory of breast carcinogenesis whereby LCIS
and ER-positive DCIS are grouped as precursors of ER-
positive invasive cancer, and ER-negative DCIS is a
precursor of ER-negative invasive cancer, regardless of
histologic grade [26].
As LCIS is usually a small, incidentally detected lesion,
most prior reports assessing clonality between LCIS and
adjacent malignancies were based on FFPE samples.
These studies also suggest clonality between LCIS and
adjacent breast carcinomas, despite the fact that they dif-
fered in terms of methodology [6,7,27,28]. Our re-analy-
sis of the publically available data from the study by
Hwang and colleagues [7] using our own statistical meth-
ods provided classification results broadly consistent with
our own results. The use of fresh frozen tissue samples
and SNP arrays in our study allows for a substantially
increased resolution for assessing clonal relatedness.
Wagner and colleagues analyzed LOH in 10 cases of
co-existent ipsilateral DCIS, LCIS, and invasive carci-
noma [27]. LOH was investigated in 13 commonly
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Figure 1 Genome-wide histograms of allelic gains and losses. The proportions of samples with copy number gains (blue) or losses (red) are
displayed at each genetic location. DCIS, ductal carcinoma in situ; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; LCIS, lobular
carcinoma in situ.
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Figure 2 Examples of genome-wide segmentation patterns of tumor pairs. (A) Case #122. (B) Case #84. (C) Case #93. Each dot represents a
log ratio; that is, allelic copy number relative to the reference normal value on log scale. In the absence of gains or losses, this should be zero.
Known or suspected germline copy number variations were filtered out prior to constructing these plots. Regions of significant gain used in
clonality comparison are highlighted in blue, while regions of loss are highlighted in red. DCIS, ductal carcinoma in situ; ILC, invasive lobular
carcinoma; LCIS, lobular carcinoma in situ.
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markers), chromosome 17 (two markers), and chromo-
somes 1, 8, 9, 11, and 13 (one marker each). In five
cases, the authors observed phenotype concordance
among all three samples (LCIS, DCIS, and IDC) in at
least one marker. In two additional cases, concordant
LOH was found between LCIS and DCIS, but not
between LCIS and the invasive lesion. This study was
novel in suggesting evidence of clonality between LCIS
and lesions with ductal phenotype, and our own results
provide substantive support for this conclusion. We
found definitive or probable clonality in three out of
four LCIS-DCIS pairs and among all three lesions in
two LCIS-DCIS-invasive cancer case triplets (Case #95
and Case #110). All clonal pairs displayed concordant
ER-positivity between paired lesions, yet the subsequent
lesions were not restricted to low-grade disease. This
finding is consistent with our previous work demon-
strating a prominent role for ER status over grade in
breast cancer progression in a historical cohort of
women with in situ and subsequent invasive lesions
[29], and adds to the growing body of literature that
suggests low-grade and high-grade ER-positive tumors
are more similar to each other than to their ER-negative
counterparts [26].
Our results also suggest that LCIS and DCIS can have
the same cell of origin and therefore may be part of a
morphological spectrum of the same precursor lesion.
Although pathologists often use E-cadherin staining to
distinguish between these two lesions, IHC has many
well-described pitfalls [30-35] and many pathologists pre-
fer to differentiate these lesions based on morphology
alone. If newly proposed models of breast carcinogenesis
are validated, whereby both ER-positive LCIS and DCIS
behave as precursor lesions to low-grade ER-positive
breast cancer, this distinction may become less clinically
relevant.
While results to date provide broad support for clonal-
ity among synchronous lobular lesions, the data favoring
clonality among LCIS and subsequent (metachronous)
invasive cancers are less clear. Aulmann and colleagues
studied nine patients with LCIS who developed subse-



















Figure 3 Detailed plots of examples of matching allelic gains and losses in Case #84. Copy number plots specific to the chromosome arm
are provided for examples of probable clonal allelic changes. Details of all arms for all comparisons are provided in Additional File 4. DCIS, ductal
carcinoma in situ; LCIS, lobular carcinoma in situ.
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IDC cases) between 2 and 10 years after the index biopsy
[6]. All cases (LCIS and invasive) showed an ER-positive/
HER2-negative profile. This study was based on compari-
sons of mitochondrial DNA heteroplasmy by PCR, direct
sequencing, and phylogenetic tree clustering, and used
microdissected samples from FFPE tissue. They observed
identical patterns of heteroplasmy in two out of five pairs
of LCIS and ILC. In one case the changes were more
complex in ILC than in LCIS, and in two pairs of LCIS
and ILC the changes favored unrelatedness. Similarly, in
all four pairs of LCIS and subsequent IDC, the changes
favored unrelatedness. More work examining metachro-
nous cancers is needed to better understand the clonal
relationship between primary cancers and subsequent
recurrences.
Despite the extensive data available to us from copy
number profiling, the classification of cases as clonal ver-
sus independent is far from a litmus test. Ideally, the histo-
gram plot of our likelihood ratio measure (Figure 4, red
histogram) would separate clearly into two distinct groups:
one group overlapping the reference (black histogram) dis-
tribution, representing the independent pairs; and one
group clearly separated, representing the clonal pairs. We
do see a clear separation for some pairs that can be confi-
dently classified as clonal. However, the histogram also
includes several tumor pairs in an intermediate grey zone
at the upper tail of the reference distribution (P < 0.05)
but within the range of values obtained by pairing tumors
from different patients. This phenomenon could have
various causes. Tumor evolution following clonal diver-
gence would tend to lead to a mixed pattern of matching
and nonmatching allelic changes. This concept has been
hypothesized to account for the wide range of histologic
and molecular diversity seen within many ductal in situ
lesions and may also explain the proposed evolution from
low-grade to high-grade disease among ER-positive lesions
[36,37]. Alternatively, contamination of the tumor samples
with normal cells or technical artifacts will tend to obscure
true signals, making it harder for our statistical algorithm
to detect them clearly. The algorithm is especially useful
in assessing the evidence for and against clonal relatedness
in these difficult cases.
Others have attempted to determine clonality based on
the presence of concordant mutations, yet this methodol-
ogy can be limited by the fact that sporadic mutations
happen recurrently at the same point in some tumors. For
example, the BRAF point mutation (T1799A) occurs in
45% of papillary thyroid carcinomas and is associated with
poor clinical outcome, but its high frequency limits its use-
fulness to address clonality [38]. In contrast, inactivating
mutations of the E-cadherin gene that occur at dozens of
different locations within the gene are highly frequent in
infiltrating lobular breast carcinomas and in diffuse gastric
carcinomas. The specificity of the mutations makes this
gene much more informative regarding clonal relatedness.
These mutations can be small insertions or deletions and
are frequently combined with LOH of the wild-type allele
[39-42]. Mutations in E-cadherin have been found at very
















Figure 4 Histogram of measures of similarity. Plot of the distribution of our measure of clonality for the individual comparisons of tumor
pairs (red histogram). The black reference histogram is obtained by comparing all pairs of tumors from different patients. Since these pairs are
definitively nonclonal they provide the reference distribution, which is used to permit calculation of the P values of the real pairings. The scale of
the horizontal axis is the log-likelihood ratio (logLR), our measure of evidence in favor of clonality. The vertical axes represent the frequencies of
pairs in the samples: left axis, black (reference) histogram; right axis, red (sample) histogram.
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Figure 5 Representative photomicrographs: Case #95, lobular carcinoma in situ-ductal carcinoma in situ-invasive cancer triplet. (A), (B)
Terminal duct lobular units involved by classic lobular carcinoma in situ (LCIS): (A) H & E, 40×; (B) H & E, 100×. (C), (D) High-grade ductal
carcinoma in situ (DCIS) with solid and micropapillary patterns: (C) H & E, 40×; (D) H & E, 100×. (E), (F) Focus of high-grade DCIS (arrows) and
associated invasive ductal carcinoma of no special type of moderate tubule formation and intermediate nuclear grade - histologic grade II/III: (E)
H & E, 40×; (F) H & E, 100×.
Andrade et al. Breast Cancer Research 2012, 14:R103
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Figure 6 Genome-wide segmentation: Case #95, lobular carcinoma in situ-ductal carcinoma in situ-invasive cancer triplet. Regions of
significant gain used in clonality comparison are highlighted in blue, while regions of loss are highlighted in red. DCIS, ductal carcinoma in situ;
IDC, invasive ductal carcinoma; LCIS, lobular carcinoma in situ.
Figure 7 Case #84: classic lobular carcinoma in situ and associated low-grade ductal carcinoma in situ. (A) Terminal duct lobular units
expanded by classic lobular carcinoma in situ (LCIS; H & E, 200×). (B) Lack of membranous E-cadherin immunoreactivity on LCIS cells. The
residual luminal cells show strong membrane staining (E-cadherin, 100×). (C) Low-grade ductal carcinoma in situ (DCIS) showing a prominent
cribriform pattern (H & E, 100×). (D) Strong, uniform membrane staining with E-cadherin on DCIS cells (E-cadherin, 100×).
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Figure 8 Case #76: lobular carcinoma in situ and associated invasive mammary carcinoma with mixed components. (A), (B) Classic
lobular carcinoma in situ (LCIS) with no membranous reactivity for E-cadherin. Residual luminal cells show membrane staining: (A) H & E, 100×;
(B) E-cadherin, 100×. (C), (D) Focus of LCIS (arrows) and lobular component of the invasive mammary carcinoma (arrowheads) with no E-
cadherin immunoreactivity: (C) H & E, 100×; (D) E-cadherin, 100×. (E), (F) E-cadherin-negative invasive mammary carcinoma cells (arrowheads)
surrounding a normal duct concentrically in a targetoid pattern: (E) H & E, 100×; (F) E-cadherin, 40×. (G), (H) Ductal component of the invasive
mammary carcinoma showing tubule formation (arrows) and strong, uniform membrane staining with E-cadherin: (G) H & E, 40×; (H) E-cadherin,
100×.
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early non-invasive stages of these diseases, leading to an
association between E-cadherin mutations and loss of
growth control, and to the classification of E-cadherin as a
candidate tumor suppressor. Data regarding the presence
of coincident mutations in E-cadherin among LCIS and
adjacent invasive cancers have been mixed. In an early
report, Vos and colleagues presented two LCIS-ILC pairs
with matching point mutations [12]. Rieger-Christ and
colleagues, however, found no matches in a series of eight
patients in which mutations were detected in LCIS-inva-
sive pairs [42]. Germline mutations of the E-cadherin gene
have been described in families with hereditary diffuse gas-
tric carcinomas, and family members are also at increased
risk for invasive lobular cancers; however, germline muta-
tions have not been identified among women with LCIS
outside these kindreds [39,43-45].
Our statistical method compares all areas of gains and
losses for a pair of samples, examines the concordance
of the starting and ending points within chromosomes,
and compares the degree of similarity of changes of an
individual pair to a reference distribution created with
samples paired from different patients. This provides a
stronger argument for clonality than any single concor-
dant point mutation. The use of an empirical reference
distribution created using pairs of tumors from different
patients is especially important since we observed some
similar patterns of copy number variation between dif-
ferent patients. For example, the presence of 1q gain
and 16q loss, consistently reported in low-grade lesions
of ductal and lobular morphology, was present in 73%
and 53% of our LCIS cases, respectively, and therefore
these changes are not very meaningful in an analysis of
clonal relatedness.
We recruited all women in a defined period present-
ing for risk-reducing or therapeutic mastectomy, but we
only aimed to harvest fresh frozen LCIS for DNA
extraction in a proportion of them; as a result, this
group may not be representative of all women harboring
LCIS. While this small prospective study confirms to us
that LCIS is likely to be associated with ER-positive and
low-grade disease, the lack of a larger group with ER-
negative and more high-grade histology prevents us
from drawing broad conclusions on the characteristics
of clonally related lesions.
Conclusions
In summary, high-resolution genome mapping using
fresh frozen microdissected samples suggests clonality
between classic LCIS and a substantial proportion of
adjacent malignant synchronous lesions of lobular and
ductal phenotype. Both low-grade and high-grade DCIS
and invasive lesions showed high degrees of similarity
with patient-matched LCIS. The ER status was
concordant in all lesions considered to be clonal or
equivocal. These data support the recent theory of
breast carcinogenesis where LCIS and ER-positive DCIS
are grouped as precursors of ER-positive invasive cancer,
and where ER-negative DCIS is a precursor of ER-nega-
tive invasive cancer, regardless of histologic grade.
Additional material
Additional file 1: Supplemental Table 1 presenting characteristics of
antibodies and protocols used in immunohistochemistry.
Additional file 2: Supplemental Table 2 presenting frequencies of
whole-arm gains/losses. Table shows the percentages of tumors for
which the segmentation algorithm identified a whole-arm gain or loss.
Additional file 3: Genome-wide plots, analogous to Figure 2.
Additional file 4: Magnified version of genome-wide plots with
detailed marker plots and segmentation on a chromosome-arm-
specific basis.
Additional file 5: Representative photomicrographs of Case #122
and Case #93. Case #122: LCIS and paired invasive lobular carcinoma of
pleomorphic morphology. (A), (B) LCIS of pleomorphic morphology with
no E-cadherin immunoreactivity. Residual luminal cells show membrane
staining: (A) H & E, 40×; (B) E-cadherin, 100×. (C), (D) Focus of LCIS
(arrows) and associated invasive lobular carcinoma (ILC, arrowheads)
both of pleomorphic morphology showing lack of membranous
reactivity for E-cadherin: (C) H & E, 40×; (D) E-cadherin, 100×. (E), (F) ILC
pleomorphic variant with no positivity with E-cadherin staining as
opposed to a normal duct. The inset image at 400× magnification
illustrates tumor cells with abundant eosinophilic cytoplasm and high
nuclear grade in a single-file infiltrating pattern: (E) H & E, 40×; (F) E-
cadherin, 40×. Case #93: LCIS and associated invasive lobular carcinoma
with no immunoreactivity for E-cadherin. (A) Classic LCIS and invasive
lobular carcinoma (ILC) surrounding a normal duct (H & E, 40×). (B) E-
cadherin staining shows lack of membranous reactivity in LCIS and ILC as
opposed to the adjacent normal terminal duct (E-cadherin, 40×).
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